IN Control clinical audit: INsulin INitiation and INtensification to avoid clinical INertia

Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. Therapeutic inertia (delays in advancing therapy when appropriate) can increase patients’ risk of diabetic complications, as they may remain above target HbA1c for many years. Delays in the initiation, titration and intensification of insulin are particularly prevalent globally.

Accredited activity aim

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.

Why take part in this program?

• Evaluate and improve glycaemic management in 5 patients with a step-by-step process of best practice and guidelines.
Earn up to 40 RACGP CPD points or 6 ACRRM PDP hours upon completion.

Learning outcomes

• Review glycaemic management in patients who may benefit from insulin initiation or intensification.
• Overcome therapeutic inertia barriers hindering insulin initiation or intensification.
• Utilise approaches for initiating or intensifying insulin therapy according to best practice management.
• Implement a plan for regular review of glycaemic control in patients with type 2 diabetes within your practice.

Inclusion criteria

The patient must have a diagnosis of type 2 diabetes with HbA1c >7% [53 mmol/mol] AND is

• Currently prescribed basal insulin (but not bolus, co-formulated or premix insulin) and identified as someone who may benefit from insulin intensification
  OR
• An insulin-naïve patient taking multiple OADs who may benefit from insulin initiation

How long should it take?

The program has been designed to take approximately 4-6 weeks to complete. This includes patient recall from your practice, patient consult and program evaluation.

Tips to recruit patients

Recruitment may occur:

• Opportunistically as you consult appropriate patients as part of usual care.
• By active recall.

Show/hide tips on identifying eligible patients for this clinical audit.

This activity is sponsored by Novo Nordisk.